This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

IDEC-151

Biogen, Inc.

Drug Names(s): clenoliximab

Description: IDEC-151 targets the CD4 receptor on helper T cells. Helper T cells mediate several activities of the immune system.

IDEC-151 is a primatized antibody, meaning that it was produced in monkeys rather than mice.

Deal Structure: In February 1999, partner GlaxoSmithKline discontinued clinical development of IDEC-151, returning all rights to IDEC.


IDEC-151 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug